Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17730111 | 1.00 | HCRTR2 (0.45) | HCRTR2DRD2THRBKCNA5KCNH2 | |
| SCHEMBL11827661 | 0.83 | HCRTR2 (0.45) | HCRTR2 | |
| SCHEMBL15583266 | 0.81 | HCRTR2 (0.46) | HCRTR2ALDH1A1KDM4E | |
| SCHEMBL15583498 | 0.81 | HCRTR2 (0.46) | HCRTR2ALDH1A1KDM4E | |
| SCHEMBL12752783 | 0.81 | HCRTR2 (0.46) | HCRTR2ALDH1A1KDM4E | |
| SCHEMBL11831448 | 0.81 | RAB9A (0.51) | KCNH2MAPK1CRBN | |
| SCHEMBL11046077 | 0.81 | ESR2 (0.49) | HCRTR2DRD2THRBKCNA5KCNH2 | |
| SCHEMBL1515026 | 0.80 | DRD2 (0.59) | DRD2ALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL12603888 | 0.79 | DRD2 (0.51) | DRD2ALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL13038146 | 0.79 | DRD2 (0.51) | DRD2ALDH1A1SMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106999450-B | Immunomodulator | 弗莱塞斯生物科学公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10206893-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180325889-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-3215142-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9598422-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016073774-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| EP-0035902-B1 | 1-(4-ARYL-CYCLOHEXYL)PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-10-31 | — | — | EP | disclosed |
| US-4329353-A | ANTIEMETIC AND NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-05-11 | — | — | US | disclosed |
| EP-0035902-A1 | 1-(4-Aryl-cyclohexyl)piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | HCRTR2 364/4885DRD2 2086/4885THRB 1654/4885 |
| US-10206893-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | HCRTR2 364/4885DRD2 2086/4885THRB 1654/4885 |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | HCRTR2 364/4885DRD2 2086/4885THRB 1654/4885 |
| US-20180325889-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | HCRTR2 364/4885DRD2 2086/4885THRB 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.